A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for the Reduction of HIV Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative Individuals
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Listed as NCT00076232, this PHASE3 trial focuses on HIV Infections and HIV Seronegativity and remains completed. Sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), it has been updated 7 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Apr 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Mental Health (NIMH)
- National Institute on Drug Abuse (NIDA)
For direct contact, visit the study record on ClinicalTrials.gov .